+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Female Sexual Dysfunction Treatment Market 2019-2023 - Product Image

Global Female Sexual Dysfunction Treatment Market 2019-2023

  • ID: 4801865
  • Report
  • June 2019
  • Region: Global
  • 108 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AMAG Pharmaceuticals Inc.
  • Duchesnay Inc.
  • Emotional Brain BV
  • Novo Nordisk AS
  • MORE
Global Female Sexual Dysfunction Treatment Market: About this market

Treating female sexual dysfunction linked to a hormonal cause might include estrogen therapy and androgen therapy while non-hormonal cause includes ospemifene (Osphena) and flibanserin (Addyi). This female sexual dysfunction treatment market analysis considers sales from both non-hormonal therapy, and hormonal therapy. Our analysis also considers the sales of female sexual dysfunction treatment in Asia, Europe, North America, and ROW. In 2018, the hormonal therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as rising prevalence of chronic diseases and increasing use of drugs that lead to sexual dysfunction in women will play a significant role in the hormonal therapy segment to maintain its market position. Also, our global female sexual dysfunction treatment market report also looks at factors such as increasing prevalence of chronic diseases, growing awareness of female sexual dysfunction, approval and availability of drug to treat hypoactive sexual desire disorder. However, adverse effects of drugs used in female sexual dysfunction treatment, lack of approved drugs, social stigma associated with female sexual dysfunction may hamper the growth of the female sexual dysfunction treatment over the forecast period.

Global Female Sexual Dysfunction Treatment Market: Overview

Increasing prevalence of chronic diseases

Female sexual dysfunctions can be caused due to various chronic diseases such as diabetes. Patients with diabetes may have several clinical conditions, including overweight, hypertension, metabolic syndrome, and atherogenic dyslipidemia, which are risk factors for sexual dysfunction in women. Therefore, rising prevalence of these conditions across the globe is expected to increase the patient pool with a large number of women having sexual dysfunctions, which, in turn, will drive the growth of the global female sexual dysfunction treatment market at a CAGR close to 37% during the forecast period.

Increasing use of drugs causing sexual dysfunctions in women

There are several classes of drugs such as antidepressants, antipsychotics, antiepileptics, and contraceptives, which result in sexual dysfunction in women. Drugs such as beta blockers decrease sexual desire in women. Alpha-adrenergic drugs also reduce sexual desire and arousal in women. Similarly, antidepressants drugs cause sexual difficulties. Furthermore, the majority of sexual dysfunction is caused by dopamine receptor blockade. Thus, the use of such drugs will increase the incidences of sexual dysfunctions in women, thereby increasing the demand for drugs to treat sexual dysfunctions in women.

Competitive Landscape

With the presence of few major players, the global female sexual dysfunction treatment market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female sexual dysfunction treatment manufacturers, that include AMAG Pharmaceuticals Inc., Duchesnay Inc., Emotional Brain BV, Novo Nordisk AS, and Sprout Pharmaceuticals Inc.

Also, the female sexual dysfunction treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AMAG Pharmaceuticals Inc.
  • Duchesnay Inc.
  • Emotional Brain BV
  • Novo Nordisk AS
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Non-hormonal therapy - Market size and forecast 2018-2023
  • Hormonal therapy - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing R&D for treatment of sexual dysfunctions in women
  • Safety label changes for female sexual dysfunction therapy
  • Increasing use of drugs causing sexual dysfunctions in women
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AMAG Pharmaceuticals Inc.
  • Duchesnay Inc.
  • Emotional Brain BV
  • Novo Nordisk AS
  • Sprout Pharmaceuticals Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Non-hormonal therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Non-hormonal therapy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Hormonal therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Hormonal therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by type
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
Exhibit 29: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 31: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 33: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: AMAG Pharmaceuticals Inc. - Vendor overview
Exhibit 44: AMAG Pharmaceuticals Inc. - Business segments
Exhibit 45: AMAG Pharmaceuticals Inc. - Organizational developments
Exhibit 46: AMAG Pharmaceuticals Inc. - Key offerings
Exhibit 47: Duchesnay Inc. - Vendor overview
Exhibit 48: Duchesnay Inc. - Key offerings
Exhibit 49: Emotional Brain BV - Vendor overview
Exhibit 50: Emotional Brain BV - Key offerings
Exhibit 51: Novo Nordisk AS - Vendor overview
Exhibit 52: Novo Nordisk AS - Business segments
Exhibit 53: Novo Nordisk AS - Organizational developments
Exhibit 54: Novo Nordisk AS - Geographic focus
Exhibit 55: Novo Nordisk AS - Segment focus
Exhibit 56: Novo Nordisk AS - Key offerings
Exhibit 57: Sprout Pharmaceuticals Inc. - Vendor overview
Exhibit 58: Sprout Pharmaceuticals Inc. - Key offerings
Exhibit 59: Validation techniques employed for market sizing
Exhibit 60: Definition of market positioning of vendors


Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AMAG Pharmaceuticals Inc.
  • Duchesnay Inc.
  • Emotional Brain BV
  • Novo Nordisk AS
  • MORE
The following companies are recognised as the key players in the global automotive steering lock system market: AMAG Pharmaceuticals Inc., Duchesnay Inc., Emotional Brain BV, Novo Nordisk AS, and Sprout Pharmaceuticals Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing use of drugs causing sexual dysfunctions in women.”

According to the report, one of the major drivers for this market is the increasing prevalence of chronic diseases

Further, the report states that one of the major factors hindering the growth of this market is the social stigma associated with female sexual dysfunction.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AMAG Pharmaceuticals Inc.
  • Duchesnay Inc.
  • Emotional Brain BV
  • Novo Nordisk AS
  • Sprout Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
Adroll
adroll